---
title: "醫療保健行業因資金輪動進入滯後板塊而上漲——醫療保健行業綜述"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286822335.md"
description: "醫療公司獲得了收益，因為交易者將注意力轉向表現不佳的行業。然而，再生元製藥在其用於黑色素瘤的 fianlimab 藥物的晚期研究失敗後，股價大幅下跌。此外，一名美國人在剛果民主共和國感染了埃博拉病毒，正值疫情持續爆發之際"
datetime: "2026-05-18T21:34:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286822335.md)
  - [en](https://longbridge.com/en/news/286822335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286822335.md)
---

# 醫療保健行業因資金輪動進入滯後板塊而上漲——醫療保健行業綜述

Health-care companies rose as traders rotated into some lagging sectors.

Regeneron Pharmaceuticals shares fell sharply in premarket trading Monday after the biotechnology company reported a late-stage study failure of its fianlimab drug candidate in the skin cancer melanoma.

An American contracted Ebola while working in the Democratic Republic of Congo, where the outbreak of the fatal virus is spreading.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 18, 2026 17:26 ET (21:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### 相關股票

- [REGN.US](https://longbridge.com/zh-HK/quote/REGN.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md)
- [再生元製藥因第三階段黑色素瘤試驗失敗股價下跌 10%。那麼，接下來 REGN 股票會如何表現呢？](https://longbridge.com/zh-HK/news/286811938.md)
- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [華爾街看好健康保險板塊，分析師上調多家公司評級](https://longbridge.com/zh-HK/news/287081375.md)
- [Scholar Rock 將出席傑富瑞全球醫療保健大會，聚焦 SMA 新藥 apitegromab 關鍵審批](https://longbridge.com/zh-HK/news/287069556.md)